As a side effect of the broad inclusion criteria, regardless of tumor type, stage of disease, drug regimens, number of previous lines of therapy, response to previous therapy, duration of follow-up and so on, the heterogeneity was increased, giving raise to the possibility of different results when focusing on more narrow patient types or more specific drug regimens (our study included VEGF blockade, VEGF-R inhibitors and angiopoietin inhibitors). The gene discussed is KDR; the disease is neoplasm.